The efficacy of gabapentin in reducing pain intensity and postoperative nausea and vomiting following laparoscopic cholecystectomy
A meta-analysis
Lifeng Wang, MD, Yucai Dong, MD, Jiling Zhang, MD, Hongwu Tan, MD

Abstract
Background: It is unknown whether gabapentin is effective in reducing acute pain following laparoscopic cholecystectomy. The purpose of the current meta-analysis was to evaluate the efficacy of gabapentin in reducing pain intensity and postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.

Methods: All randomized controlled trials (RCTs) evaluating the efficacy of gabapentin in reducing pain intensity and PONV after laparoscopic cholecystectomy were searched on the following databases: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Google database, the Chinese Wanfang database, and the China National Knowledge Infrastructure (CNKI). The most recent literature search was conducted on March 21, 2017. Outcomes including visual analog scale (VAS) at 12 and 24 hours, total morphine consumption, and the occurrence of PONV. Continuous outcomes were expressed as the weighted mean difference (WMD) and 95% confidence interval (CI), and the one discontinuous outcome was expressed as risk ratio (RR) and 95% CI. Stata 12.0 software was used for meta-analysis.

Results: A total of 9 studies involving 966 patients were identified. In total, there were 484 gabapentin subjects and 482 controls. Compared with the control group, gabapentin was associated with lower VAS at 12 hours (WMD = −10.18, 95% CI: −17.36 to −2.80; P = .007) and 24 hours (WMD = −6.33, 95% CI: −8.41 to −4.25, P = .000), which was equivalent on a 110-point VAS scale to 10.18 points at 12 hours and 6.33 points at 24 hours. Compared with the control group, gabapentin was associated with less total morphine consumption by approximately 110.83 mg (WMD = −110.83, 95% CI: −183.25 to −38.42, P = .003). In addition, the occurrence of nausea and vomiting in gabapentin was decreased (25.2% vs 47.6%, RR = 0.44–0.63, P = .000).

Conclusion: Gabapentin was efficacious in reducing postoperative pain, total morphine consumption, and morphine-related complications following laparoscopic cholecystectomy. In addition, there was a negative correlation between the gabapentin dosage and the occurrence of nausea and vomiting. The number of included studies is limited, and more studies are needed to verify the effects of gabapentin in laparoscopic cholecystectomy patients.

Abbreviations: CBM = Chinese Biomedical Database, CENTRAL = the Cochrane Central Register of Controlled Trials, CI = confidence interval, CNKI = China National Knowledge Infrastructure, PONV = postoperative nausea and vomiting, RCTs = randomized controlled trials, RR = risk ratio, TKA = total knee arthroplasty, VAS = visual analog scale, WMD = weighted mean difference.

Keywords: gabapentin, laparoscopic cholecystectomy, meta-analysis

1. Introduction
Postoperative pain, nausea, and vomiting are common complications of laparoscopic cholecystectomy.11 It is reported that approximately of 53% to 72% of patients undergoing laparoscopic cholecystectomy require antiemetics after surgery.12,31 Reduction of postoperative pain can shorten patients’ hospital stays and promote functional recovery.14 Traditionally, opioids are the first option for the treatment of moderate to severe pain after surgery. However, the side effects of opioid analgesics, such as nausea and vomiting, limit the clinical use of those drugs.15,6

Gabapentin is an antiepileptic drug that also has therapeutic effects on diabetic neuropathy and herpes zoster neuropathic pain.17,31 In addition, gabapentin may reduce postoperative acute pain by reducing central sensitization.19 Recent meta-analyses show that gabapentin can reduce the amount of opioid use after abdominal hysterectomy, spinal surgery, and orthopedic surgeries.18,19 Gabapentin has used for pain control in patients following laparoscopic cholecystectomy without conclusive results.15,14 In addition, there is no systematic review and meta-analysis to assess the efficacy and safety of gabapentin in reducing pain following laparoscopic cholecystectomy. The purpose of the current meta-analysis was to determine whether preoperative treatment with gabapentin is associated with lower pain scores, total morphine consumption, and postoperative...
nausea and vomiting (PONV) following laparoscopic cholecystectomy.

2. Materials and methods

This is a meta-analysis and thus no ethical approval was necessary.

2.1. Inclusion criteria and exclusion criteria

**Inclusion criteria—**Study type: clinical RCTs; Participants: patients prepared for laparoscopic cholecystectomy (ASA 3 and 4); Intervention: the experimental group received preoperative oral gabapentin, while the control group received a placebo or blank control. Outcomes: visual analog score (VAS) at 12 and 24 hours, total morphine consumption, and the occurrence of PONV.

**Exclusion criteria—**Comparison with other drugs (glucocorticoid or pregabalin); Noninclusion of gabapentin drugs; Non-RCTs; Comments or with no relevant outcomes.

2.2. Search strategies

We systematically searched RCTs that investigated the preoperative use of gabapentin for the treatment of laparoscopic cholecystectomy pain from PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Google database, the Chinese Wanfang database, and the China National Knowledge Infrastructure (CNKI). The most recent literature search was conducted on March 21, 2017. The search terms in the PubMed database were: ‘((“Cholecystectomy, Laparoscopic”[Mesh]) OR laparoscopic cholecystectomy)) AND gabapentin. There were no restrictions regarding language or publication date. We also manually retrieved reference lists from the identified studies and relevant review studies to identify additional relevant studies.

2.3. Quality assessment

The quality of all included trials was independently assessed by 2 reviewers (LW and YD) on the basis of the Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (http://handbook.cochrane.org/).[15] The evaluation criteria include 7 items: random sequence generation; allocation concealment; blind method (patients and healthcare providers); blind outcome assessment; incomplete outcome data; selective outcome reporting; and other bias. The criteria were evaluated as low risk, unclear, or high risk. Finally, Review Manager 5.3.0 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) was applied to generate graphics. Meanwhile, the Jadad score was used to quantitatively evaluate the quality of RCTs.[16] The Jadad score including 3 items: random sequence generation, blinding, and dropouts. Low-quality articles have a Jadad score between 1 and 3; high-quality articles have a Jadad score between 4 and 7.[17]

2.4. Data extraction

A specific extraction was conducted to assemble data into a pregenerated standard Microsoft Excel (Microsoft Corporation, Redmond, WA) file. The items extracted from relevant studies were as follows: first author and publication year, sample size of the intervention and control groups, preoperative doses, timing and frequency and the total dose of gabapentin per number of days and follow-ups. Outcomes such as the VAS at 12 and 24 hours and the occurrence of nausea and vomiting were abstracted and recorded in the spreadsheet. Postoperative pain intensity was measured using a 110-point VAS (0 = no pain and 100 = extreme pain). When the numerical rating scale (NRS) was reported, it was converted to a VAS. Additionally, the 11-point VAS was converted to a 110-point VAS.[18] Data in other forms (i.e., median, interquartile range, and mean ± 95% confidence interval (CI)) were converted to the mean ± standard deviation (SD) according to the Cochrane Handbook.[15] If the data were not reported numerically, we extracted these data using the “GetData Graph Digitizer” software from the published figures. All the data were extracted by 2 independent reviewers (L-FW and Y-CD), and disagreements were resolved by discussion.

2.5. Statistical analysis

Statistical analysis was performed using Stata 12.0 software (Stata Corp., College Station, TX). The continuous outcomes (VAS at 12 and 24 hours and total morphine consumption) were expressed as the weighted mean difference (WMD) and 95% CI, and the discontinuous outcome (the occurrence of PONV) was compared using the risk ratio (RR) and 95% CI. The heterogeneity between the studies was assessed using the I² test; if I² was less than or equal to 50%, there was no obvious heterogeneity, and a fixed-effect model (Mantel–Haenszel) was applied to the data. We used a random effects model if I² was more than 50%. Subgroup analysis was conducted according to the dosage of gabapentin (<900 or ≥900 mg/d). The relationship between the gabapentin dosage and the VAS at 12 and 24 hours was explored using GraphPad Prism software (Version 6.0; GraphPad Software, San Diego, CA). The correlation coefficient (r) was used to evaluate the relationship between the dosage of gabapentin and the occurrence of nausea and vomiting. Statistical significance was defined as P < .05. To measure the robustness of the pooled results and avoid a type I error,[19–21] trial sequence analysis (TSA) was performed for the primary outcome (TSA software, version 0.9.5.5 beta; Copenhagen Trial Unit, Copenhagen). Power analyses of individual studies and meta-analyses were all conducted by software PS (Power and Sample Size Calculations, London) version 3.0.43.

3. Results

3.1. Search results

The flow diagram for the included studies can be seen in Fig. 1. According to the search strategy, a total of 688 studies were retrieved (PubMed = 121, Embase = 85, Web of Science = 49, Cochrane Library = 55, Google database = 109, Chinese Biomedical Database (CBM) = 100, VIP database = 38, China Wanfang database = 59, China National Knowledge Infrastructure (CNKI) = 72). Then, the literatures were imported into Endnote software (Version X7, Thompson Reuters, CA) to exclude the duplicates. Then, a total of 418 articles were excluded at the title and abstract level. Finally, a total of 9 RCTs with 966 patients were included in this meta-analysis.[13,14,23–29]

3.2. General characteristic and quality assessment

The general information of the patients is shown in Table 1. The publication years ranged from 2004 to 2016. The numbers of
Gabapentin and control subjects ranged from 20 to 153. The total gabapentin dosages ranged from 300 to 1200 mg per day. Finally, the follow-up times ranged from 24 hours to 1 week. The general characteristic of the included studies were comparable and all studies describe the intent to treat analyses.

The risk of bias summary and risk of bias graph are provided in Figs. 2 and 3, respectively. The risk of bias for random sequence generation and allocation concealment was unclear in 5 studies and low in 4 studies. Blinding of participant and personnel was unclear in 4 studies and the rest all had low risk of bias. We used Jadad score to assess the RCTs, and the results are displayed in Table 2. The Jadad scores were 2 in 3 studies, 3 in 2 studies, and 5 in 4 studies. The quality of all of the studies were acceptable. The individual study’s power was ranged from 65.3% to 72.9%. The power of the meta-analysis of the total studies was 86.4%.

Figure 1. Flowchart of study search and inclusion criteria.
3.3 Results of meta-analysis

3.3.1 VAS at 12 hours. Five papers involving 508 patients analyzed the VAS at 12 hours, and there was substantial statistical heterogeneity among the studies ($I^2 = 95.0\%$, $P = .000$). Compared with the control treatments, gabapentin reduced the intraoperative VAS at 12 hours, and the difference was statistically significant ($WMD = -10.18$, 95% CI: $-17.36$ to $-2.80$, $P = .007$, Fig. 4). We then tested the publication bias using the funnel plot and Begg test; the results are shown in Figs. 5 and 6, respectively. The effect size was found to be symmetrical, and Begg value was 0.952.

3.3.2 VAS at 24 hours. Five studies including 508 patients reported the postoperative VAS at 24 hours. There was statistical heterogeneity between the studies ($I^2 = 55.7\%$, $P = .060$), and thus a random effects model was used to perform the meta-analysis. Compared with the control treatments, gabapentin reduced postoperative VAS at 24 hours, and the difference was statistically significant ($WMD = -6.33$, 95% CI: $-8.41$ to $-4.25$, $P = .000$, Fig. 7).

3.4 Total morphine consumption

Five studies including 706 patients reported the total morphine consumption. There was statistical heterogeneity between the studies ($I^2 = 99.5\%$, $P = .000$), and therefore a random effects model was used to perform the meta-analysis. Compared with the control treatments, gabapentin reduced total morphine consumption after laparoscopic cholecystectomy, and the difference was statistically significant ($WMD = -110.83$, 95% CI: $-183.25$ to $-38.42$, $P = .003$, Fig. 8).

3.5 The occurrence of nausea and vomiting

Seven studies including 864 patients analyzed the occurrence of PONV. There was little statistical heterogeneity between the studies ($I^2 = 33.4\%$, $P = .173$), and thus a fixed effect model was used to perform the meta-analysis. Compared with the control group, gabapentin reduced the occurrence of PONV, and the difference was statistically significant ($RR = 0.53$, 95% CI: $0.44$–$0.63$, $P = .000$, Fig. 9).

| Refs. | Age, y | Female, % | No. of patients | Intervention | Total dose, mg | Control | Outcomes | Follow-up | Study |
|-------|--------|-----------|-----------------|--------------|----------------|---------|----------|-----------|-------|
| Mishra et al[23] | 37 | 35.7 | 68.9 | 65.4 | 30 | 900 mg a day 2 h before anesthetic induction | 900 | Placebo (n = 30) | 2, 3, 4 | 24 h | RCTs |
| Bashir et al[24] | 45.7 | 51.3 | 70 | 80 | 50 | 600 mg a day 2 h before operation | 900 | Placebo (n = 50) | 1 | 1 wk | RCTs |
| Kotsovolis et al[25] | 48.4 | 53.1 | 65.2 | 58.7 | 24 | 600 mg 4h before surgery and 24 h after surgery | 1200 | Placebo (n = 24) | 1 | 72 h | RCTs |
| Pandey et al[26] | 42.8 | 41.8 | 80 | 85.6 | 125 | 600 mg a day 2h before surgery | 300 | Placebo (n = 125) | 1.4 | 24 h | RCTs |
| Heguo 2009[14] | 49.9 | 44.1 | 56.8 | 60.1 | 20 | 300 mg a day 2 h before anesthesia induction | 300 | Placebo (n = 20) | 1.2, 3 | 24 h | RCTs |
| Yuan 2009[27] | 43.4 | 41.7 | 45.4 | 50.1 | 21 | 300 mg a day 2 h before surgery | 300 | Placebo (n = 21) | 2, 3, 4 | 24 h | RCTs |
| Xuliang 2009[28] | NS | NS | NS | NS | 30 | 300 mg a day 2 h before surgery | 300 | Placebo (n = 30) | 1.2, 3 | 24 h | RCTs |
| Xudong 2008[29] | 51.3 | 52.4 | 51.6 | 51.7 | 31 | 600 mg a day 1 h before surgery | 600 | Placebo (n = 31) | 1 | 24 h | RCTs |

RCTs = randomized controlled trials, NS = not stated.
Table 2

| Refs.          | Was the study described as randomized? | Was the method used to generate the sequence of randomization described and appropriate? | Was the study described as double blind? | Was the method of double blind described and appropriate? | Was there a description of withdraw and dropouts? | Total score |
|----------------|----------------------------------------|--------------------------------------------------------------------------------------------|------------------------------------------|----------------------------------------------------------|-----------------------------------------------------|-------------|
| Mishra et al[23] | 0                                      | 0                                                                                         | 1                                        | 1                                                         | 1                                                   | 3           |
| Bashir et al[24]  | 1                                      | 1                                                                                         | 1                                        | 1                                                         | 1                                                   | 5           |
| Kotsovolis et al[25] | 1                                      | 1                                                                                         | 1                                        | 1                                                         | 1                                                   | 5           |
| Pandey et al[13]  | 1                                      | 1                                                                                         | 1                                        | 1                                                         | 1                                                   | 5           |
| Pandey et al[26]  | 1                                      | 1                                                                                         | 1                                        | 1                                                         | 1                                                   | 5           |
| Yuan 2009[27]     | 0                                      | 0                                                                                         | 1                                        | 1                                                         | 1                                                   | 3           |
| Xulong 2009[28]   | 0                                      | 0                                                                                         | 0                                        | 1                                                         | 1                                                   | 2           |
| Xudong 2009[29]   | 0                                      | 0                                                                                         | 0                                        | 1                                                         | 1                                                   | 2           |
| Heguo 2009[14]    | 0                                      | 0                                                                                         | 0                                        | 1                                                         | 1                                                   | 2           |

Figure 3. Risk of bias graph.

Figure 4. Forest plots of the included studies comparing the VAS at 12 hours.
3.6. Dose–effect relationship

We plotted the gabapentin dosage on the abscissa, with the corresponding PONV as the ordinate, to generate a scatterplot. In addition, the linear correlation coefficient ($r$) was calculated. There was a negative correlation between the dosage of gabapentin and PONV ($r = -0.754$, $P = .041$, Fig. 10). The occurrence of nausea and vomiting tended to decrease as the gabapentin dosage increased.

3.7. Subgroup analysis

Subgroup analysis results are available in Table 3. The pooled results indicated that a high dosage of gabapentin was superior to a low dosage in reducing VAS at 12 and 24 hours, total morphine consumption, and the occurrence of nausea and vomiting ($P < .05$).

3.8. TSA results

TSA results shown that the accumulative Z-curve crossed the trial sequential monitoring boundary for benefit after the trials. A TSA confirmed the VAS at 12 hours (Fig. 11A), VAS at 24 hours (Fig. 11B), total morphine consumption (Fig. 11C), and the occurrence of nausea and vomiting (Fig. 11D). These results provided firm evidence of a significant reduction in VAS at 12 hours, VAS at 24 hours, total morphine consumption, and the occurrence of nausea and vomiting in the gabapentin group. Meanwhile, the sample was sufficient to provide firm conclusion.
Figure 8. Forest plots of the included studies comparing the total morphine consumption.

Figure 9. Forest plots of the included studies comparing the occurrence of nausea and vomiting.
4. Discussion

This is the first systematic review and meta-analysis to assess the effects of gabapentin on postoperative acute pain and PONV in patients following laparoscopic cholecystectomy. The final results indicated that preoperative treatment with gabapentin was associated with lower pain scores at 12 and 24 hours postoperatively. In addition, gabapentin decreased the total morphine consumption and the occurrence of nausea and vomiting. After a comprehensive search of multiple electronic databases, a total of 9 studies were included in this meta-analysis. A major strength of the current meta-analysis was the statistical rigor with which the outcomes were calculated.

The pooled results indicated that preoperative administration of gabapentin was associated with lower pain scores postoperatively, which was equivalent on a 110-point VAS to 10.18 points at 12 hours and 6.33 points at 24 hours. Arumugam et al.\(^{30}\) performed a meta-analysis involving 17 RCTs with 1793 surgical patients, and their results indicated that gabapentin is an effective analgesic adjunct in patients undergoing elective surgery. Fabritius et al.\(^{31}\) indicated that evidence for the use of gabapentin was different from experiment to experiment; thus, the confidence level of this outcome is relatively high due to the low heterogeneity between the included studies. We then determined the dose–effect relationship between the gabapentin dosage and the occurrence of nausea and vomiting. In the included studies, we also tried to compare other complications between the gabapentin and control groups. However, there were insufficient data to extend the meta-analysis to other complications.

There were several limitations in the current meta-analysis: the quality of 4 of the articles was low, which likely resulted in selective bias; the heterogeneity of the VAS at 12 and 24 hours and the total morphine consumption was large and made it difficult to draw a definitive conclusion, though subgroups and a random effects model were used to minimize heterogeneity; the supplementary pain control measures in the included studies were different and thus may have introduced heterogeneity; the dosage of gabapentin was different from experiment to experiment; thus, the optimal dosage of gabapentin requires further study; the occurrence of PONV was measured only in 7 studies and also a great limitation.

In conclusion, immediate analgesic efficacy and opioid-sparing effects (PONV) were obtained with the administration of gabapentin. Additionally, the analgesic efficacy and opioid-sparing effects were obvious in the high-dosage gabapentin group. Thus, we recommend routinely administration high

### Table 3

| Variables                        | Incidence | Weighted mean difference/risk ratio (95% CI) | Heterogeneity P (I²) | Model | Subgroup difference |
|----------------------------------|-----------|---------------------------------------------|----------------------|-------|---------------------|
| VAS at 12h                       |           |                                             |                      |       |                     |
| High dose                        | 2         | 240                                         | .012                 | −12.20 (−17.46, −6.94) | 800, 0.0 | Fixed              | 0.021 |
| Low dose                         | 3         | 274                                         | .000                 | −10.88 (−14.11, −3.51) | 0.03, 82.5 | Random             |       |
| VAS at 24h                       |           |                                             |                      |       |                     |
| High dose                        | 2         | 240                                         | .010                 | −10.23 (−15.46, −5.00) | 0.00, 88.3 | Random             | 0.013 |
| Low dose                         | 3         | 274                                         | .001                 | −9.50 (−10.76, −2.25)  | 0.00, 83.9 | Random             |       |
| Total morphine consumption       |           |                                             |                      |       |                     |
| High dose                        | 2         | 260                                         | .002                 | −125.37 (−233.45, −17.28) | 0.00, 52.3 | Random             | 0.016 |
| Low dose                         | 3         | 285                                         | .000                 | −53.74 (−62.59, −44.89) | 0.00, 73.1 | Random             |       |
| The occurrence of nausea and vomiting |       |                                             |                      |       |                     |
| High dose                        | 3         | 406                                         | .011                 | 0.45 (0.30, 0.83)      | 0.62, 0.0 | Fixed              | 0.001 |
| Low dose                         | 4         | 340                                         | .161                 | 0.63 (0.40, 1.63)      | 0.81, 0.0 | Fixed              |       |

CI = confidence interval, VAS = visual analog scale.
dose of gabapentin in reducing acute pain after laparoscopic cholecystectomy. Because the sample size and the number of included studies were limited, a multicenter RCT is needed to clarify the optimal dose and timing of gabapentin in reducing acute pain after laparoscopic cholecystectomy.

References

[1] Wang N, Wang L, Gao Y, et al. Analgesic effect of preoperative pentazocine for laparoscopic cholecystectomy. Cureus 2016;8:e948.
[2] Naguib M, el Bakry AK, Khoshim MH, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996;43:226–31.
[3] Pertusa V, Belver J, Marques A, et al. [Antiemetic prophylaxis after laparoscopic cholecystectomy: comparative study of dehydrobenzperidol, metoclopramide, ondansetron and placebo]. Rev Esp Anestesiol Reanim 1996;43:239–42.
[4] Fuji Y. The utility of antiemetics in the prevention and treatment of postoperative nausea and vomiting in patients scheduled for laparoscopic cholecystectomy. Curr Pharm Des 2005;11:3173–83.
[5] Park IJ, Kim G, Ko G, et al. Does preoperative administration of gabapentin/pregabalin improve postoperative nasal surgery pain? Laryngoscope 2016;126:2232–41.
[6] Dong J, Li W, Wang Y. The effect of pregabalin on acute postoperative pain in patients undergoing total knee arthroplasty: a meta-analysis. Int J Surg 2016;34:148–60.
[7] Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; Cd007938.
[8] Miranda HF, Sierralta F, Jorquera V, et al. Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy. Inflammopharmacology 2017;25:91–7.
[9] Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin? Neurourol Urodyn 2017[Epub ahead of print].
[10] Yu L, Ran B, Li M, et al. Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis. Spine (Phila Pa 1976) 2013;38:1947–52.
[11] Achuthan S, Singh I, Varthya SB, et al. Gabapentin prophylaxis for postoperative nausea and vomiting in abdominal surgeries: a quantitative analysis of evidence from randomized controlled clinical trials. Br J Anaesth 2015;114:588–97.
[12] Mao Y, Wu L, Ding W. The efficacy of preoperative administration of gabapentin/pregabalin in improving pain after total hip arthroplasty: a meta-analysis. BMC Musculoskelet Disord 2016;17:373.
[13] Pandey CK, Priye S, Ambesh SP, et al. Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. J Postgrad Med 2006;52:97–100.
[14] Heguo L, Haitao M, Jianhua C, et al. Antiemetic effect of gabapentin in patients undergoing laparoscopic cholecystectomy. China J Endosc 2009;15:492–4.

[15] Green S, Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available at: http://handbook.cochrane.org/. 2011. Access 2011.

[16] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.

[17] Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2017;12:e0172846.

[18] Wang C, Cai X-Z, Yan S-G. Comparison of periarticular multimodal drug injection and femoral nerve block for postoperative pain management in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2015;30:1281–6.

[19] Thorlund K, Devereaux PJ, Weterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? J R Soc Med 2009;13:276–86.

[20] Thorlund K, Imberger G, Walsh M, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis—a simulation study. PLoS ONE 2011;6:e25491.

[21] Brok J, Thorlund K, Gluud C, et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61:763–9.

[22] Brok J, Thorlund K, Weterslev J, et al. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol 2009;38:287–98.

[23] Mishra R, Tripathi M, Chandola HC. Comparative clinical study of gabapentin and pregabalin for postoperative analgesia in laparoscopic cholecystectomy. Anesth Essays Res 2016;10:201–6.

[24] Bashir F, Mohd K, Qazi S, et al. A randomized, double blind placebo controlled study evaluating preventive role of gabapentin for PONV in patients undergoing laparoscopic cholecystectomy. JK Sci J Med Educ Res 2009;11:190–3.

[25] Kotsovolis G, Karakoulas K, Groumanidis V, et al. Comparison between the combination of gabapentin, ketamine, lornoxicam, and local ropivacaine and each of these drugs alone for pain after laparoscopic cholecystectomy: a randomized trial. Pain Pract 2015;15:355–63.

[26] Pandey CK, Priye S, Singh S, et al. Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirements in laparoscopic cholecystectomy. Can J Anaesth 2004;51:338–63.

[27] Yuan C, Yuanchang X. Effect of gabapentin on postoperative pain during anaesthetic period of laparoscopic cholecystectomy. Acad J Second Mil Med Univ 2009;30:972–4.

[28] Xiang W, Xiaoning Y, Ling Q. Application of preemptive analgesia of gabapentin in laparoscopic cholecystectomy. J Southeast China Natl Defence Med Sci 2009;11:9–2.

[29] Xudong X. The efficacy of gabapentin in the laparoscopic cholecystectomy. J Clin Anesthesiol 2008;24:1083–7.

[30] Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. J Pain Res 2016;9:631–40.